Protocol Ledger

NCT03253679 · Phase II · COMPLETED

AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

Interventional Phase II clinical trial protocol NCT03253679 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-01-16 Enrollment: 31 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03253679
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)31 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03253679
Protocol FieldVerified Registry Value
NCT IdentifierNCT03253679
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment31 participants (ACTUAL)
Registered Start Date2019-01-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI